15th Annual



Friday, November 30 | San Francisco, CA

California Life Sciences AssociationCalifornia Life Sciences Association

Outstanding Product



Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

The company’s latest advancement, the MiniMed 670G system is the world’s first hybrid closed loop insulin delivery system, which automates and personalizes the delivery of basal insulin 24 hours a day in people with type 1 diabetes. The system features our most advanced algorithm to date, SmartGuard HCL, which enables the personalized delivery of insulin based on the unique needs of each user, maximizing the time sugar levels are within what’s referred to as the “target range” – a range where sugar levels are considered healthy by clinical standards. It is designed to learn what an individual’s insulin needs are and to take action to reduce exposure to both high and low sugar levels. This algorithm is powered by the Guardian Sensor 3, Medtronic’s newest and most accurate sensor to date. The Guardian Sensor 3 is the first and only sensor approved by the FDA to control a hybrid closed loop system and it incorporates advanced diagnostic technology that continuously monitors sensor health. As a result, with the sensor, the system requires minimal input – patients only need to enter mealtime carbohydrates, accept bolus correction recommendations, and periodically calibrate the sensor. With the MiniMed 670G launch, Medtronic is leading the industry in its phased approach towards developing a fully automated, closed loop system to help people with diabetes enjoy greater freedom and better health.

The Diabetes Group at Medtronic is part of Medtronic plc, the global leader in medical technology.